MediciNova, Inc. Form 10-Q Summary
Business Context and Reporting Period
MediciNova is a development-stage biopharmaceutical company focused on acquiring and developing small-molecule therapeutics for serious diseases with unmet medical needs. The report covers the three months ended March 31, 2013, and was filed May 8, 2013.
Primary development focus was MN-166 for neurological disorders. The company was also seeking funding or a partner to advance MN-221 for acute asthma and COPD. The company remained pre-commercial and had incurred significant losses since inception.
Financial Performance and Liquidity
| Metric | Q1 2013 | Q1 2012 |
|---|---|---|
| Revenue | $3,257 | $191,174 |
| Research and development expense | $695,972 | $1,878,461 |
| General and administrative expense | $1,724,579 | $2,185,972 |
| Total operating expenses | $2,420,551 | $4,064,433 |
| Operating loss | $2,417,294 | $3,873,259 |
| Net loss applicable to common stockholders | $2,419,014 | $3,867,223 |
| Basic and diluted loss per share | $0.14 | $0.24 |
| Net cash used in operating activities | $2,621,901 | $3,427,147 |
Revenue consisted primarily of recognition of the Kissei research and development services upfront payment. The company reported no cost of revenues in either quarter. Profit margins were not meaningful because revenue was minimal and the company operated at a substantial loss.
At March 31, 2013, cash and cash equivalents were $3.0 million, compared with $4.0 million at December 31, 2012. Working capital was $2.8 million. Total assets were $18.8 million and total liabilities were $4.6 million. The company reported no debt and no interest expense in the quarter. Cash equivalents included approximately $1.1 million of money market investments.
Financing activities provided $1.6 million during the quarter, primarily from common stock issuance. Cash declined by $981,466 during the quarter to $3.0 million. Management stated that available cash was sufficient to fund operations through approximately September 30, 2013, creating substantial doubt about the company’s ability to continue as a going concern.
Material Changes Versus the Prior Comparable Period
- Revenue decreased approximately $188,000, or about 98%, primarily because the MN-221 COPD clinical trial-related services performed under the Kissei agreement were substantially completed in 2012.
- Research and development expense decreased $1.2 million, primarily because MN-221 spending declined by approximately $1.0 million following completion of the CL-007 and CL-012 trials, and stock-based compensation declined.
- General and administrative expense decreased approximately $461,000, primarily due to lower employee compensation and stock-based compensation.
- Net loss improved by approximately $1.4 million, while basic and diluted loss per share improved from $0.24 to $0.14, partly reflecting a higher weighted-average share count.
- Cash used in operations improved by approximately $805,000, but remained substantially above reported revenue.
- Common shares issued increased to 18.3 million at March 31, 2013 from 17.4 million at December 31, 2012, reflecting equity financing and other issuances.
Outlook, Commentary, Risks, and Unusual Items
The FDA granted Fast Track designation to MN-166 in February 2013. Clinical trials in methamphetamine and opioid addiction were ongoing, including a Phase 1b trial near completion at UCLA and NIDA-funded studies. Future MN-221 clinical development was to be partner-dependent after FDA feedback indicating that a clinical outcome, such as reduced hospitalizations, would be needed as a pivotal-trial endpoint.
The company expected continued substantial losses and low spending on most other product candidates, while limiting expenditures to activities needed to maintain license rights or maximize value. No quantitative revenue or earnings guidance was provided.
After quarter-end, the company entered into a $6 million at-the-market equity distribution agreement with Macquarie Capital. Through the filing date, it had received $2.8 million of net proceeds from selling 895,000 shares. It also reported total proceeds of $4.3 million under the Aspire Capital agreement, including $1.4 million from post-quarter-end sales. These financings provide liquidity but may materially dilute existing shareholders.
The former employee litigation was dismissed by an arbitrator on April 30, 2013, with approximately $100,000 of monetary sanctions awarded to the company. The company stated that it had no other material changes to previously disclosed risk factors, except the dilution and potential share-price impact associated with the Macquarie equity sales.
Important Facts for Investors to Verify
- Whether additional equity financing can extend the company’s cash runway beyond the approximately September 30, 2013 estimate.
- The pace, pricing, and dilution from Aspire and Macquarie share sales.
- Progress, funding, and clinical results for MN-166, including the NIDA-funded addiction trials.
- Whether a strategic partner can be secured to fund future MN-221 development.
- The remaining balance and recognition schedule of the Kissei deferred revenue.
- The company’s going-concern disclosure and ability to obtain financing on acceptable terms.
- Potential future milestone, licensing, clinical-trial, regulatory, manufacturing, litigation, and commercialization costs.